The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

Teva Pharmaceutical Industries ( NYSE:TEVA ) Full Year 2024 Results Key Financial Results Revenue: US$16.5b (up 4.4... This pharma stock has made strong gains over the past 12 months thanks to its ...

In February 2025, Teva Pharmaceuticals and Alvotech announced ... The press release highlights potential safety concerns associated with SELARSDI, including an increased risk of serious infections ...

This marks the second biosimilar released in the U.S. by the strategic partnership between Teva Pharmaceuticals and ... The press release highlights significant safety concerns associated with ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows ... visit www.tevapharm.com. Appendix - key information from Teva's Generics Health Check 3.0 ...

Teva and Alvotech's Selarsdi, like Stelara, is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ...